Condensed Consolidated Financial Statement Details (Tables)

6 Months Ended

Jun. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following (in thousands):

	June 30, 2023		December 31, 2022
Raw materials	$	2,045	$	2,575
Work-in-process	12,879		10,749
Finished goods	5,765		5,878
Total inventory	$	20,689	$	19,202

Schedule of Other Current Assets

Other current assets consist of the following (in thousands):

	June 30, 2023		December 31, 2022
Prepaid research and development expenses	$	3,265	$	7,398
Other prepaid expenses	3,804		5,987
Non-trade receivables and other	2,533		2,423
Total other current assets	$	9,602	$	15,808

Schedule of Property, Plant and Equipment

Property, plant and equipment consists of the following (in thousands):

	June 30, 2023		December 31, 2022
Building and leasehold improvements	$	62,526	$	74,889
Computer equipment and computer software	24,623		26,205
Manufacturing equipment	25,404		25,052
Laboratory equipment	13,109		24,243
Furniture, fixtures and other	4,068		4,263
Depreciable property, plant and equipment at cost	129,730		154,652
Less: accumulated depreciation	(107,637)		(124,731)
Depreciable property, plant and equipment, net	22,093		29,921
Construction in process	461		2,530
Property, plant and equipment, net	$	22,554	$	32,451

Schedule of Goodwill

The following is a reconciliation of the changes in our goodwill for the six months ended June 30, 2023 (in thousands):

	Six months ended June 30, 2023
Goodwill – beginning balance	$	76,501
Impairment of goodwill	(76,501)
Goodwill – ending balance	$	—

Schedule of Accrued Expenses

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	June 30, 2023		December 31, 2022
Accrued compensation	$	10,670	$	9,582
Accrued clinical trial expenses	5,517		12,262
Liability to collaboration partners	4,472		3,808
Accrued contract termination costs	3,084		3,902
Other accrued expenses	5,399		7,003
Total accrued expenses	$	29,142	$	36,557

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the six months ended June 30, 2023 (in thousands):

	Six Months Ended June 30, 2023
	2012 Purchase and Sale Agreement		2020 Purchase and Sale Agreement		Total
Liabilities related to the sales of future royalties, net – beginning balance	$	55,167	$	100,211	$	155,378
Non-cash royalty revenue	(17,496)		(15,197)		(32,693)
Non-cash interest expense	2,538		10,019		12,557
Amortization of transaction costs	—		417		417
Liabilities related to the sales of future royalties, net – ending balance	$	40,209	$	95,450	$	135,659

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):

	Foreign currency translation		Available-for-sale securities		Accumulated Other Comprehensive Income
Balance at December 31, 2022	$	(5,131)	$	(1,776)	$	(6,907)
Foreign currency translation adjustments	139		—		139
Unrealized gain on available-for-sale securities	—		1,087		1,087
Balance at March 31, 2023	$	(4,992)	$	(689)	$	(5,681)
Foreign currency translation adjustments	13		—		13
Unrealized gain on available-for-sale securities	—		244		244
Reclassification adjustments to income	(1,026)		—		(1,026)
Balance at June 30, 2023	$	(6,005)	$	(445)	$	(6,450)